Effects of doxorubicin and gemcitabine on the induction of apoptosis in breast cancer cells

Zheng,Rui-Rui; Hu,Wei; Sui,Cheng-Guang; Ma,Nan; Jiang,You-Hong

doi:10.3892/or.2014.3513

Effects of doxorubicin and gemcitabine on the induction of apoptosis in breast cancer cells

Authors:
- Rui-Rui Zheng
- Wei Hu
- Cheng-Guang Sui
- Nan Ma
- You-Hong Jiang
View Affiliations

Affiliations: Cancer Research Institute, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: September 24, 2014 https://doi.org/10.3892/or.2014.3513
Pages: 2719-2725

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer-related mortality in females worldwide. The efficacy of chemotherapeutic drugs on breast cancer is hindered by many factors, including that cancer stem-like side population (SP) cells may contribute to tumorigenesis and resistance to chemotherapy. Doxorubicin and gemcitabine are two of the most effective and widely used chemotherapeutic agents for the treatment of various human malignancies. To the best of our knowledge, the effects of doxorubicin and gemcitabine on breast cancer SP cells are poorly understood. In the present study, we examined the potential roles of doxorubicin and gemcitabine in breast cancer main population (MP) and SP cells, and the mechanisms of doxorubicin and gemcitabine. The results showed that doxorubicin and gemcitabine decreasede proliferation, and increased apoptosis in the MCF7 MP and SP cells in vitro. Furthermore, doxorubicin and gemcitabine inhibited tumor growth and improved the survival rate of mice in vivo. Additionally, the mechanisms of doxorubicin and gemcitabine in MCF7 MP and SP cells were determined.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Glück S and Gorouhi F: Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer. Am J Health Syst Pharm. 68:1699–1706. 2011.PubMed/NCBI
3	Noto A, Raffa S, De Vitis C, et al: Stearoyl-CoA desaturase-1 is a key factor for lung cancer-initiating cells. Cell Death Dis. 4:e9472013. View Article : Google Scholar : PubMed/NCBI
4	Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
5	Xia P, Gou WF, Zhao S and Zheng HC: Crizotinib may be used in Lewis lung carcinoma: A novel use for crizotinib. Oncol Rep. 30:139–148. 2013.PubMed/NCBI
6	Ho MM, Ng AV, Lam S and Hung JY: Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 67:4827–4833. 2007. View Article : Google Scholar : PubMed/NCBI
7	Haraguchi N, Utsunomiya T, Inoue H, et al: Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells. 24:506–513. 2006. View Article : Google Scholar : PubMed/NCBI
8	Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 346:92–98. 2002. View Article : Google Scholar
9	Spielmann M, Llombart-Cussac A, Kalla S, et al: Single-agent gemcitabine is active in previously treated breast cancer. Oncology. 60:303–307. 2001. View Article : Google Scholar : PubMed/NCBI
10	Plunkett W, Huang P, Xu YZ, et al: Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 22(Suppl 11): S3–S10. 1995.
11	Chatterjee K, Zhang J, Honbo N and Karliner JS: Doxorubicin cardiomyopathy. Cardiology. 115:155–162. 2010. View Article : Google Scholar
12	Takemura G and Fujiwara H: Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis. 49:330–352. 2007. View Article : Google Scholar : PubMed/NCBI
13	Gibbs CP, Kukekov VG, Reith JD, et al: Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia. 7:967–976. 2005. View Article : Google Scholar : PubMed/NCBI
14	Xu J, Peng H and Zhang JT: Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy. Curr Med Chem. 14:689–701. 2007. View Article : Google Scholar : PubMed/NCBI
15	Zhang JT: Biochemistry and pharmacology of the human multidrug resistance gene product, ABCG2. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 32:531–541. 2007.PubMed/NCBI
16	Kanzaki A, Toi M, Neamati N, et al: Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma. Jpn J Cancer Res. 93:70–77. 2002. View Article : Google Scholar : PubMed/NCBI
17	Robey RW, Ierano C, Zhan Z and Bates SE: The challenge of exploiting ABCG2 in the clinic. Curr Pharm Biotechnol. 12:595–608. 2011. View Article : Google Scholar : PubMed/NCBI
18	Zhou J, Wang CY, Liu T, et al: Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J Gastroenterol. 14:925–930. 2008. View Article : Google Scholar : PubMed/NCBI
19	Bergman AM, Pinedo HM, Talianidis I, et al: Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer. 88:1963–1970. 2003. View Article : Google Scholar
20	Nobili S, Landini I, Giglioni B and Mini E: Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets. 7:861–879. 2006. View Article : Google Scholar : PubMed/NCBI
21	Liu ZH and Lenardo MJ: Reactive oxygen species regulate autophagy through redox-sensitive proteases. Dev Cell. 12:484–485. 2007. View Article : Google Scholar : PubMed/NCBI
22	Xia P, Gou WF, Wang JJ, et al: Distinct radiosensitivity of lung carcinoma stem-like side population and main population cells. Cancer Biother Radiopharm. 28:471–478. 2013. View Article : Google Scholar : PubMed/NCBI
23	Xing YN, Deng P and Xu HM: Canstatin induces apoptosis in gastric cancer xenograft growth in mice through mitochondrial apoptotic pathway. Biosci Rep. Apr 2–2014.(Epub ahead of print).
24	Phillips TM, McBride WH and Pajonk F: The response of CD24^−/low/CD44⁺ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 98:1777–1785. 2006.PubMed/NCBI